Testosterone Regulates Tight Junction Proteins and Influences Prostatic Autoimmune Responses

被引:45
作者
Meng J. [1 ]
Mostaghel E.A. [1 ,2 ]
Vakar-Lopez F. [3 ]
Montgomery B. [2 ]
True L. [3 ]
Nelson P.S. [1 ,2 ,3 ]
机构
[1] Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, D4-100
[2] Department of Oncology, University of Washington, Seattle, WA
[3] Department of Pathology, University of Washington, Seattle, WA
来源
Hormones and Cancer | 2011年 / 2卷 / 3期
关键词
Claudin; Inflammation; Testosterone supplementation; Tight junction;
D O I
10.1007/s12672-010-0063-1
中图分类号
学科分类号
摘要
Testosterone and inflammation have been linked to the development of common age-associated diseases affecting the prostate gland including prostate cancer, prostatitis, and benign prostatic hypertrophy. We hypothesized that testosterone regulates components of prostate tight junctions which serve as a barrier to inflammation, thus providing a connection between age- and treatment-associated testosterone declines and prostatic pathology. We examined the expression and distribution of tight junction proteins in prostate biospecimens from mouse models and a clinical study of chemical castration, using transcript profiling, immunohistochemistry, and electron microscopy. We determined that low serum testosterone is associated with reduced transcript and protein levels of Claudin 4 and Claudin 8, resulting in defective tight junction ultrastructure in benign prostate glands. Expression of Claudin 4 and Claudin 8 was negatively correlated with the mononuclear inflammatory infiltrate caused by testosterone deprivation. Testosterone suppression also induced an autoimmune humoral response directed toward prostatic proteins. Testosterone supplementation in castrate mice resulted in re-expression of tight junction components in prostate epithelium and significantly reduced prostate inflammatory cell numbers. These data demonstrate that tight junction architecture in the prostate is related to changes in serum testosterone levels, and identify an androgen-regulated mechanism that potentially contributes to the development of prostate inflammation and consequent pathology. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码:145 / 156
页数:11
相关论文
共 50 条
[1]  
Cunha G.R., Donjacour A.A., Cooke P.S., Et al., The endocrinology and developmental biology of the prostate, Endocr Rev, 8, pp. 338-362, (1987)
[2]  
Pritchard C.C., Nelson P.S., Gene expression profiling in the developing prostate, Differentiation, 76, pp. 624-640, (2008)
[3]  
Hayward S.W., Cunha G.R., The prostate: Development and physiology, Radiol Clin North Am, 38, pp. 1-14, (2000)
[4]  
Coffey D.S., Pienta K.J., New concepts in studying the control of normal and cancer growth of the prostate, Prog Clin Biol Res, 239, pp. 1-73, (1987)
[5]  
Huggins C., Hodges C.V., Studies on prostate cancer 1: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, Cancer Res, 1, pp. 293-297, (1941)
[6]  
Andriole G., Bruchovsky N., Chung L.W., Et al., Dihydrotestosterone and the prostate: The scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia, J Urol, 172, pp. 1399-1403, (2004)
[7]  
Rittmaster R.S., 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction, Best Pract Res Clin Endocrinol Metab, 22, pp. 389-402, (2008)
[8]  
Feldman H.A., Longcope C., Derby C.A., Et al., Age trends in the level of serum testosterone and other hormones in middle-aged men: Longitudinal results from the Massachusetts male aging study, J Clin Endocrinol Metab, 87, pp. 589-598, (2002)
[9]  
Harman S.M., Metter E.J., Tobin J.D., Pearson J., Blackman M.R., Longitudinal effects of aging on serum total and free testosterone levels in healthy men, Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab, 86, pp. 724-731, (2001)
[10]  
Makhsida N., Shah J., Yan G., Fisch H., Shabsigh R., Hypogonadism and metabolic syndrome: implications for testosterone therapy, J Urol, 174, pp. 827-834, (2005)